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ABSTRACT
Objective: Pharmacokinetic evaluation of montelukast sodium chronomodulated capsules (sustained-release solid dispersion of drug enclosed in 
pH-sensitive film-coated hard gelatin shell) and marketed tablets has been carried out in this study.
Methods: A single oral dose of prepared capsules and marketed conventional tablets was administered in healthy male Dunkin-Hartley albino guinea 
pigs. Blood samples were collected at different time intervals and plasma concentration of drug was determined by reversed-phase high-performance 
liquid chromatography. Different pharmacokinetic parameters were assessed from plasma drug concentration-time profile by one-compartment 
model, first-order kinetics.
Results: Pharmacokinetic parameters such as time to reach maximum concentration, elimination rate constant, elimination half-life, and mean 
residence time data indicates that drug release from chronomodulated capsules is significantly prolonged with initial release lag time of 3.5–4 h 
in comparison with marketed conventional tablets. However, maximum drug plasma concentration, area under the concentration-time curve, and 
apparent volume of distribution values show non-significant difference between capsules and marketed tablets.
Conclusion: The findings specified that capsules were providing time controlled delivery of drug at a desired rate for prolonged time, which may be 
helpful for the prevention of episodic attack of asthma in early morning hours.
Keywords: Montelukast sodium, Pharmacokinetics, High-performance liquid chromatography, Guinea pig plasma, Sustained-release solid dispersion, 
pH-sensitive coating.
INTRODUCTION
Pharmacokinetics is a study of drug disposition in the body and focuses 
on the changes in the blood drug concentration over time [1]. The 
pharmacokinetic characteristics can be quantitatively expressed by its 
parameters such as maximum drug plasma concentration, time to reach 
maximum concentration, area under the concentration-time curve 
(AUC), elimination rate constant (Kel), elimination half-life (t1/2), mean 
residence time (MRT), clearance, and apparent volume of distribution 
(Vd). Compartment models are used in pharmacokinetics as a tool 
to compute and analyze the parameters that help to describe the 
experiment results [2].
Montelukast sodium (MS) is a leukotriene receptor antagonist and 
advised for once-daily oral dosing for the management of symptoms 
associated with asthma in children and adults [3,4]. Montelukast 
is an effective, well-tolerated alternative to inhaled corticosteroids 
treatment in patients with mild asthma who are uncontrolled or 
unsatisfied with low-dose inhaled corticosteroids therapy [5]. MS salt 
has a high-molecular-weight (608.169 g/mol), with solubility in water 
is approximately at a concentration of 10 mg/ml [6]. Montelukast 
works by blocking a chemical reaction that perpetuates inflammation 
in airways [7]. This is an acidic drug which is highly bound to plasma 
albumin and 64% bioavailable orally [8,9]. The main drawback of 
conventional montelukast formulation is that it undergoes hepatic 
first-pass metabolism and shows biological half-life of 2.5–5 h [10]. 
Chronomodulated capsules (sustained-release solid dispersion of drug 
enclosed in pH-sensitive film-coated hard gelatin shell) are designed to 
have initial 3.5–4 h release lag time with sustained release up to 10 h 
assuming that capsules to be consumed at bedtime. This approach was 
consistent with the demand of drug during early morning hour attack 
of asthma. Asthma is a chronic inflammatory disorder of the airways 
which has significant effect on patient’s health and quality of life [11].
The present study brought out the pharmacokinetic characteristics of 
MS chronomodulated capsules administered to guinea pig.
MATERIALS AND METHODS
Materials
MS was received from Sanofi Aventis, Goa, India, as a gift sample. 
Metoclopramide hydrochloride was obtained from Vaikunth Chemicals 
Pvt., Ltd., Gujarat, India. All other chemicals and reagents were of 
analytical grade or high-performance liquid chromatography (HPLC) 
grade procured from E-Merk (India) Ltd., and Fluka chemicals.
Methods
Pharmacokinetic design and analysis
Institutional animal ethical committee (1044/PO/Re/S/07/CPCSEA, 
ITS/01/IAEC/2017) I.T.S College of Pharmacy, Ghaziabad, was 
approved the study protocol.
Chromatographic conditions
The analysis was carried out reversed-phase HPLC, equipped with 
intelligent ultraviolet (UV)-visible spectrophotometry detector (Jasco 
UV-2075, Japan), autosampler, Cosmosil5C18-MS-II (4.6 ID×250 MM) 
column, and pump (Jasco Intelligent Pump, 2080 Plus, Japan). Column 
temperature was set as 25–27°C, run time; 10 min, and wavelength; 
287 nm. The mobile phase consisted of the mixture of acetonitrile 
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and sodium acetate buffer (20 mM, pH adjusted to 5.0) in the ratio 
of 80:20 v/v was delivered at a flow rate of 1.5 ml/min, isocratically. 
Ultrasonic bath was used to remove dissolved gases and entrapped air 
in mobile phase. Vortex mixer (Remi CM-101 Plus, India) and cooling 
centrifuge (Remi CM-12 Plus, India) were used for sample processing.
The bioanalytical method was adopted as described earlier by Ranjan 
et al., 2013, and Shafaati et al., 2010, after performing partial method 
validation [12,13].
Plasma sample preparation for calibration curve
Calibration curve of MS was prepared by spiking of 800 µl of the 
guinea pig plasma samples with 100 µl of previously prepared 
working solutions of concentration of 1, 2, 5, 10, 15, and 20 µg/mL, 
keeping internal standard (metoclopramide hydrochloride) solution 
concentration 8 µg/mL in each one. Accordingly, plasma samples 
contain the final concentration of MS 100, 200, 500, 1000, 1500, 
and 2000 ng/mL, respectively, with 800 ng/mL of metoclopramide 
hydrochloride as internal standard in each [14,15].
MS was extracted from plasma sample by protein precipitation 
technique using saturated NaCl solution [16]. 2.5 ml of saturated 
solution of NaCl was mixed with 1 ml of spiked plasma sample. The 
mixture was vortexed for 15 min followed by centrifugation at −4°C, 
8000 rpm for 20 min. Finally, I injected 20 µl of supernatant into HPLC 
column [12,13].
Study design, drug administration, and blood sampling
The study was carried out in six male Dunkin-Hartley albino guinea 
pigs of average weight 562 g. The animals were housed with free access 
to standard food and tap water ad libitum. The experimental animals 
were housed in air-conditioned rooms at 21–23°C and 60–65% of 
relative humidity and provide a regular light/dark cycle. Animals were 
handled as per guide for the care and use of laboratory animals and left 
to acclimatize for 2 weeks before the start of the experiment [17]. The 
overnight fasted pigs were divided into two groups having three animals 
in each group. One group was fed with developed capsule and other 
with marketed conventional tablet as a single oral dose [18-20]. After 
washout period of 20 days, the pigs were crossed over and administered 
the alternate formulation. All the animals had free access of food 
and water after 4 h of drug dosing. After a single oral administration, 
blood was collected in ethylenediaminetetraacetic acid coated tube at 
different time intervals [21]. Blood was immediately centrifuged (Remi 
CM-12 Plus, India) at 8000 rpm for 20 min at −4°C to separate plasma, 
and plasma samples were stored at −20°C±2°C for further analysis [22].
Analysis of blood samples
Frozen plasma samples were first thawed at room temperature 
and then spiked with internal standard, for this 20 µl of solution 
containing 8 µg/mL of an internal standard were added to 230 µl of 
each plasma sample, followed by drug extraction by saturated solution 
of NaCl. Plasma concentration of MS was calculated from regression 
equation and pharmacokinetic parameters were determined by one-
compartment model, first-order kinetics [23,24]. Pharmacokinetic 
parameters were calculated by the following method: AUC by linear-log 
trapezoidal method, MRT0-t=AUMC0-t/AUC0-t, MRT0-∞=AUMC0-∞/AUC0-∞, 
and Cl= dose/AUC0-t, Kel using equation ln(C0/Ct)=Kel t, where, C0 is initial 
concentration, Ct is concentration at time t, and Vd=dose/kel[AUC]0-∞.
Data and statistical analysis
The concentration-time data were collected and entered into MS Excel 
2010 worksheet. SPSS version 16.0 was used for statistical data analysis. 
The descriptive statistics (mean, standard deviation, and standard error 
Fig. 1: Calibration curve of montelukast sodium in guinea pig 
plasma
Fig. 2: Representative chromatogram of drug-free blank guinea pig plasma
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of mean) were calculated. The normality of data was tested by Shapiro–
Wilk test and data were found normal; hence, to test the significance 
of mean differences of pharmacokinetic parameters between two 
independent groups, unpaired t-test was used. The level of significance 
and confidence interval was accepted as 5% and 95%, respectively [25,26].
RESULTS
The ratio of peak area of the MS to the peak area of the internal 
standard has given a linear correlation over a concentration range of 
100–2000 ng/ml with correlation coefficient (r2) of 0.999 (Fig. 1). The 
mean regression equation was y=0.001x-0.0590, where, y is peak area 
ratio and x is the concentration of MS in plasma.
Three drug substances were examined to achieve suitable internal 
standard for guinea pig plasma analysis, among them metoclopramide 
hydrochloride was found as most suitable for quantitation of MS level. 
Representative chromatogram of blank plasma in comparison to spiked 
samples of MS at concentration ranging from 100 ng/ml to 12000 ng/ml 
with internal standard at a constant concentration of 800 ng/ml is 
shown in Figs. 2-4. Chromatograms confirmed that MS and IS were well 
separated at retention times of 4.19–8.10 min, respectively, under the 
described chromatographic conditions.
The mean pharmacokinetic parameters computed from the individual 
pharmacokinetic analysis of the MS plasma concentration-time data of 
each animal are tabulated in Table 1.
Fig. 3: Chromatogram of plasma spiked with internal standard 800 ng/ml and montelukast sodium 100 ng/ml
Fig. 4: Plasma spiked with internal standard 800ng/ml and montelukast sodium 1200 ng/ml
168
Asian J Pharm Clin Res, Vol 12, Issue 2, 2019, 165-169
 Singh, et al. 
The pharmacokinetic profile of chronomodulated capsules was 
compared with that of marketed conventional tablets (Montair 10, by 
Cipla Ltd., India) at equivalent dose and shown in Fig. 5.
DISCUSSION
Conventional tablets reached to peak plasma concentration within 2 h 
compared to 6 h for the chronomodulated capsules after a single oral 
administration. Furthermore, chronomodulated capsules demonstrated 
significantly longer t1/2 then the conventional tablets. Conventional 
tablets are immediate dosages form and release drug in gastric pH, 
but capsules release the drug in the higher pH 6.8 after dissolution of 
coating. Sustained-release pattern of capsules after lag release time of 
3.5 h leads to more uniform drug absorption and slow elimination as 
compared to conventional tablets. MRT was significantly prolonged 
for capsules due to slow elimination rate. Capsules showed complete 
release of drug in 12 h in a controlled manner by diffusion mechanism. 
The mean Cmax, Tmax, t1/2, AUC, MRT, Vd, and Ke values obtained in the 
present study (Table 1) are comparable to that described in other 
similar studies [26-29]. To determine bioequivalence of developed 
capsule with marketed conventional tablet in single-dose studies, 
Cmax and extent of absorption (AUC) were considered. The absence of 
a significant difference in the Cmax and AUC at equivalent dose under 
the same conditions and same route of administration establishes the 
bioequivalence between the two formulations in this study.
Fig. 5: Plasma concentration-time profile of montelukast sodium 
in chronomodulated capsules and conventional tablets
Table 1: Pharmacokinetic parameters of MS in 
chronomodulated capsules and marketed conventional tablets 






Cmax (ng/ml) 515.29±2.16 525.23±4.06*
Tmax (h) 6.00 2.00
T1/2 (h) 7.52±1.94 4.30±0.29
AUC0-t (ng h/ml) 4500.52±29.19 3161.96±52.17*
AUC0-∞ (ng h/ml) 5007.25±36.36 4015.67±43.75*
Kel (1/h) 0.09±0.012 0.16±0.014
Vd (L) 0.94±0.08 0.73±0.05
MRT0-t (h) 10.86±1.73 6.67±0.91
MRT0-∞ (h) 11.93±2.18 7.59±1.31
*Non-significance difference was observed. Vd: Volume of distribution, 
SEM: Standard error mean, Cmax: Maximum drug plasma concentration, 
Tmax: Time to reach maximum concentration, T1/2: Elimination half-life, 
MRT: Mean residence time, Kel: Elimination rate constant, AUC: Area under the 
concentration-time curve, MS: Montelukast sodium
CONCLUSION
The in vivo study indicates that capsules release the drug in sustained 
manner after initial predetermined lag time and may be useful for 
the better management of asthma.We compared the bioavailability of 
prepared capsules with that of commercial tablets and results show 
that the two studied formulations are bioequivalent with respect to 
Cmax and AUC.
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